Review of bleeding events in clinical studies of clopidogrel

doi:10.12092/j.issn.1009-2501.2021.03.015

Welcome to Chinese Journal of Clinical Pharmacology and Therapeutics,Today is Share:

Chinese Journal of Clinical Pharmacology and Therapeutics ›› 2021, Vol. 26 ›› Issue (3): 341-349.doi: 10.12092/j.issn.1009-2501.2021.03.015

Previous Articles Next Articles

Review of bleeding events in clinical studies of clopidogrel

^{YUAN Zhen, CHEN Bilian}

Department of Geriatrics, Xiangya Hospital, Central South University, Changsha 410078, Hunan, China

Received:2020-12-21 Revised:2021-02-06 Online:2021-03-26 Published:2021-04-06

Abstract

Abstract: P2Y12 receptor antagonist is currently one of the commonly used drugs for the treatment of acute coronary syndromes. Clopidogrel is a representative drug among P2Y12 receptor antagonists. Bleeding events as the most common side effect of this drug have also been concerned. The incidence and risk of bleeding events in large-scale clinical studies of clopidogrel are analyzed and discussed to provide refer-ences for reasonable clinical prescription of clopidogrel.

Key words: clopidogrel, bleeding events, bleeding definition

CLC Number:

R543.3
R972

YUAN Zhen, CHEN Bilian. Review of bleeding events in clinical studies of clopidogrel[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(3): 341-349.

[1]	LU Xiya, LI Yuxing, LI Wenzhi, PENG Yuanyuan, HU Yi, WAN Li, CHEN Bilian. Analysis of prescribing of antiplatelet drug in patients with coronary heart disease in department of geriatrics [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(11): 1285-1291.
[2]	XIA Chunyong, ZHANG Zuowen, HE Xiaoyan, LIU Jie, LI Xiaoya, CHANG Qiuhong, QIN Lijuan, CAO Zhenming, DING Ling. Correlation between CYP2C19 gene polymorphism and individualized medication in patients with ischemic stroke [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(3): 318-323.
[3]	XU Honglei, XU Bingxin, ZU Qing, ZHAO Yan, GAO Pengfei, YU Yang. Effects of CYP2C19 gene polymorphism on the clinical prognosis of clopidogrel in elderly patients with acute cerebral infarction [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(9): 1014-1020.
[4]	PENG Jing, LIU Jun, XU Huifang, LI Yueran, JIANG Jia, WANG Sheng, ZHOU Dexi, ZHU Yanhong, YANG Kui, LUAN Jiajie. Correlation study between cytochrome P4502C19 gene polymorphism or metabolic type and ADP induced-platelet aggregation inhibition and clopidogrel resistance [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(7): 746-751.
[5]	YANG Rui, LIU Hui, CHEN Zeheng, QI Tingting，ZHANG Zanling, QU Qiang. Clinical pharmacists use CYP2C19 genotyping test to guide individual medication therapy of Clopidogrel and to evaluate the efficacy of treatment [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2019, 24(8): 938-943.
[6]	WANG Weiyu, YU Hao. Effects of gray drugs in patients with coronary heart disease: A network Meta-analysis [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2018, 23(3): 301-307.
[7]	ZHANG Xia, KE Yong-sheng. Clinical research of new type P2Y12 Receptor inhibitor ticagrelor [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2014, 19(4): 459-464.
[8]	YANG Yong-ge, ZHANG Mei, JIANG Nan, SONG Li-xue, XU Xue-ting, DI Xiao-hui, XU Lin, XU Juan,ZHAO Gang-tao. Bioequivalence of clopidogrel hydrogen sulfate tablets in healthy Chinese volunteers [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2014, 19(1): 38-43.
[9]	YUN Wen-bo¹, JIANG Peng-li¹, WU Jing¹, SUN He^1,2. Bleeding risk is higher when warfarin used alone compared to the associated use of aspirin with clopidogrel [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2013, 18(11): 1251-1259.
[10]	LIAO Chun-xing, PAN Qiao-ling, YANG Jian-quan, ZHU De-xia, ZHANG Jun. Clopidogrel prevent late malfunction in tunneled cuffed hemodialysis catheters [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2012, 17(6): 687-690.
[11]	QIAN Jian, XU Jian. Effects of simvastatin combining clopidogrel on high-sensitivity C-reactive protein and blood lipids in patients with acute coronary syndrome [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2010, 15(2): 206-209.
[12]	HE Chun-hui, HU Qin , ZOU Jian-jun, CHEN Shao-liang, FAN Hong-wei, XIE Hong-guang, ZHU Yu-bing. Study on genetic factors of clopidogrel resistance [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2010, 15(11): 1288-1293.
[13]	CHEN Bi-lian, XIE Qin-zhi, LI Qing. Clinical observation of clopidogrel resistance and clinical outcomes on patients with acute coronary syndrome [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2009, 14(3): 328-332.
[14]	YU Chang-yong, ZHANG Yong, ZOU Jian-jun, YAN Xiang, MA Hai-tao, NI Bin, ZHU Yu-bing, FAN Hong-we, HE Chun-hui. Advances on the causes and strategies of clopidogrel resistance [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2009, 14(10): 1168-1173.
[15]	WEI Jian-rui, LI Biao, LI Qing-mei, GUO Zhuang-bo, WU Wo-dong. Effects of cilostazol combinated with clopidogrel on platelet membrane glycoprotein in patients with acute coronary artery syndrome without ST-segment elevation [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2008, 13(5): 557-562.

Review of bleeding events in clinical studies of clopidogrel

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments